PerkinElmer buys out British gene editing player for $383M, boosting its diagnostics and genomic capabilites
PerkinElmer, the Massachusetts-based diagnostics and life sciences company, has a new acquisition, and it comes with a nearly $400 million price tag.
The company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.